New diabetes drug DA-5218 aims to help when metformin Isn't enough

NCT ID NCT07229534

Not yet recruiting Disease control Sponsor: Dong-A ST Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called DA-5218 in 238 adults with type 2 diabetes whose blood sugar is not well controlled by metformin alone. Participants will receive either DA-5218 or an active comparator, and researchers will measure changes in HbA1c over time. The trial is double-blind and randomized, meaning neither patients nor doctors know who gets which treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DA-5218 (an experimental diabetes drug)
What this could lead to: If successful, DA-5218 could offer a new treatment option for people with type 2 diabetes who need better blood sugar control despite taking metformin.
What could go wrong: This is a Phase IV trial, so the drug is already approved in some form, but it may still have side effects or not work better than existing options. Results are limited to short-term blood sugar changes, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE MELLITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE MELLITUS

More trials for these conditions

Other studies related to the condition(s) this trial covers.